Lectade Plus Powder for Oral Solution

Composition

Active substances:

Each Sachet A contains:

Sodium chloride 4.59 g

Glycine 3.01 g

Potassium dihydrogen phosphate 1.36 g

Sodium acid citrate 1.80 g

Potassium citrate 3.24 g

Sodium citrate 0.66 g

Each Sachet B contains:

Glucose monohydrate 62.69 g

When reconstituted as recommended, each litre contains:

Glycine 20 mmol

Sodium 50 mmol

Potassium 20 mmol

Chloride 39 mmol

Citrate 10 mmol

Phosphate 5 mmol

Glucose 160 mmol

Excipient:

Sachet A: Pink powder

Sachet B: White powder

3

Pharmacological properties

A glucose-glycine-electrolyte formulation which is effective in oral rehydration therapy. The underlying principles of this are:

1. Intestinal absorption of glucose and amino acids is an active process linked to the movement of sodium and water.

2. The linked absorption increases net fluid and electrolyte uptake and offsets fluid loss, so reversing the process of dehydration and diarrhoea;

3. When diarrhoea is caused by bacterial enterotoxins, the active transport of glucose and glycine is not impaired;

Diarrhoea may result in dehydration, hyponatraemia, hyperkalaemia and acidosis. Effective oral rehydration therapy will reverse the net secretion of fluid and electrolytes into the gut and promote net absorption of water, electrolytes and nutrients. The active ingredients of the veterinary medicinal product act in this way. Glucose and glycine are actively absorbed by a sodium-dependent mechanism, bringing about a net uptake of water. In addition, these ingredients also act as a source of energy (glucose) and amino acids (glycine). This increased content of energy and amino acid is particularly important for the calf when milk is withheld during the treatment regime.

Sodium and chloride ions from the salt form an essential part of the sodium dependent glucose and glycine transport mechanism, which promotes the absorption of water. Potassium dihydrogen phosphate provides potassium, phosphate and hydrogen ions, helping to restore electrolyte balance. Citrate ions further enhance water uptake from the gut and indirectly provide bicarbonate to correct the acidosis of dehydration and diarrhoea. The veterinary medicinal product has extra citrate ions which aid this process.

When made up with water as directed, the veterinary medicinal product forms an isotonic solution. This is beneficial, as a hypertonic solution would promote further water secretion into the gut, so exacerbating the diarrhoea.

4.1 ATCvet code:

QA07CQ02

3

Target species

Calves.

3

Indications

The veterinary medicinal product is indicated as an oral rehydration therapy for the treatment of diarrhoea in calves by reversing the process of dehydration, acidosis and loss of electrolytes associated with diarrhoea, whether caused by bacteria, viruses, cryptosporidia or inappropriate nutrition.

3

Dosage

Oral use.

The contents of sachets A and B should be added to 2 litres (approximately 3.5 pints) of fresh water, at a temperature of about 35°C.

Scouring calves

Immediately scour symptoms show, withdraw milk or milk replacer and offer 2 litres of solution twice daily for two days (four feeds). For the next four feeds offer 1 litre of the veterinary medicinal product solution added to 1 litre of milk or milk replacer. Thereafter feed as normal.

Duration of treatment

If the scouring is established or severe, thus causing serious dehydration, the solution should be fed three or four times daily. The veterinary medicinal product may be used on its own for a maximum of four days. Ensure that adequate colostrum is fed to all calves.

General recommendations

Keep feeding utensils clean. Any medicated water which is not consumed within 24 hours should be discarded.

The reconstituted product forms a pink solution.

3

Contraindications

None.

3

Adverse reactions

Target species: Calves

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3

Warnings

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Not applicable.

Special precautions for the protection of the environment:

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3

Use during pregnancy, lactation or lay

Not applicable.

3

Interactions

None known.

The veterinary medicinal product has been shown to be compatible with oral antibiotics such as amoxicillin, ampicillin and oxytetracycline.

3

Overdose

No adverse effects are to be expected from an accidental overdose.

3

Special warnings

In severe cases of dehydration some animals may require additional intravenous re- hydration therapy. In such cases consult a veterinary surgeon.

3

Withdrawal period

Meat and offal: Zero days.

3

Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

3

Immediate packaging

The veterinary medicinal product is presented in twinned laminated sachets of two sizes. The laminate consists of paper (outside), polyethylene, aluminium foil, polyethylene (inside).

Sachet A contains 14.66 g of the electrolyte mix.

Sachet B contains 62.69 g of the glucose.

The veterinary medicinal product is available in cartons of 12 or 48 paired sachets.

Not all pack sizes may be marketed.

3

Storage

Store in a dry place.

Do not store above 25°C.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Shelf life after reconstitution according to directions: 24 hours

3

Disposal of unused product

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

3

Additional information

Vm 52127/5068 Vm 52127/3003

8 DATE OF FIRST AUTHORISATION

20 December 1993

9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

August 2026

10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product not subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Approved 18 August 2026

3

Registration holder

Elanco GmbH

3